Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Bliss Gvs Pharma Limited (BLISSGVS) Stock Price & Analysis

4 Followers

BLISSGVS Stock Chart & Stats

₹641.15-₹18.75(-2.84%)
At close: 3:30 PM GMT+5:30
₹500₹600₹700Aug 17Aug 31Sep 15Sep 28Oct 12Oct 26Nov 9
Day’s Range
INR 640.00 - INR 667.80
52-Week Range
INR 140.85 - INR 744.75
Previous Close
INR 659.90
Volume
N/A
Average Volume (3M)
14.65K
Market Cap
INR 70.17B
Enterprise Value
INR 74.66B
Total Cash (Recent Filing)
INR 1.93B
Total Debt (Recent Filing)
INR 225.57M
Price to Earnings (P/E)
42.4
Beta
0.64
Next Earnings
Jan 26, 2027 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Jul 08, 2026
Dividend Yield
0.23%

Bulls Say, Bears Say

Bulls Say

Revenue Growth

A strong revenue-growth rate indicates continued demand for the company’s medicines and expanding commercial reach. If sustained, this top-line momentum can support operating leverage, fund product development, and strengthen the company’s position across domestic and international markets.

Conservative Balance Sheet

Low and declining leverage gives Bliss GVS financial flexibility to fund operations and growth without excessive dependence on borrowing. Rising assets and equity reinforce the capital base, improving resilience while allowing management to pursue opportunities through changing pharmaceutical-market conditions.

Improving Cash Generation

Strong recent operating and free cash flow indicates that reported earnings are translating into internal funding capacity. This supports investment in products and market expansion, reduces reliance on external capital, and improves the company’s ability to sustain operations through the next several quarters.

Bears Say

Earnings Volatility

Historical margin volatility shows that profitability has not been consistently predictable, even as revenue has grown. A repeat of weaker earnings could reduce reinvestment capacity and make results more sensitive to changes in the company’s product mix or operating performance.

Choppy Cash Conversion

Uneven cash conversion means accounting profits may not consistently become available cash for investment, debt service, or shareholder returns. Working-capital or spending variability can therefore make financial planning less predictable and weaken the durability of cash generation.

Operating Profitability Clarity

Limited clarity around the relationship between EBITDA and EBIT makes it harder to assess the quality and sustainability of operating profits. This uncertainty can complicate evaluation of underlying margins and reduce confidence that recent profitability fully reflects recurring business performance.

Bliss Gvs Pharma Limited News

BLISSGVS FAQ

What was Bliss Gvs Pharma Limited’s price range in the past 12 months?
Bliss Gvs Pharma Limited lowest stock price was ₹140.85 and its highest was ₹744.75 in the past 12 months.
What is Bliss Gvs Pharma Limited’s market cap?
Bliss Gvs Pharma Limited’s market cap is ₹70.17B.
When is Bliss Gvs Pharma Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Bliss Gvs Pharma Limited’s earnings last quarter?
Bliss Gvs Pharma Limited released its earnings results on Oct 29, 2026. The company reported ₹4.92 earnings per share for the quarter.
Is Bliss Gvs Pharma Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Bliss Gvs Pharma Limited pay dividends?
Bliss Gvs Pharma Limited pays an annual dividend of ₹1 which represents an annual dividend yield of 0.23%. See more information on Bliss Gvs Pharma Limited dividends here
What is Bliss Gvs Pharma Limited’s EPS estimate?
Bliss Gvs Pharma Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bliss Gvs Pharma Limited have?
Bliss Gvs Pharma Limited has 106,330,475 shares outstanding.
What happened to Bliss Gvs Pharma Limited’s price movement after its last earnings report?
Bliss Gvs Pharma Limited reported an EPS of ₹4.92 in its last earnings report. Following the earnings report the stock price went up 4.992%.
Which hedge fund is a major shareholder of Bliss Gvs Pharma Limited?
Currently, no hedge funds are holding shares in IN:BLISSGVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology